Analyst Expectations for Ligand Pharmaceuticals’s Future
Within the last quarter, Ligand Pharmaceuticals (NASDAQ:LGND) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Ligand’s Collaborator Merck Announces V116, An Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed For Adults, Met Key Immunogenicity And Safety Endpoints In Two Phase 3 Trials
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that its collaborator Merck, known as MSD outside of the United States and Canada, today announced positive topline results from two Phase 3 trials
Why Are Novan Shares Nosediving Today?
Novan Inc (NASDAQ: NOVN) shares are trading lower after Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has offered to
Novan Enters Into Agreement To Sell Substantially All Of Its Assets, Including Berdazimer Gel, 10.3%, And Files For Chapter 11 Protection; Announces Commitment From Ligand To Fund $15M In Debtor-In-Posession Financing
– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan's assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing –
Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial
Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in
Recap: Ligand Pharmaceuticals Q1 Earnings
Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q1 earnings results on Thursday, May 4, 2023 at 04:01 PM. Here’s what…
Earnings Scheduled For May 4, 2023
Companies Reporting Before The Bell
• Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million.
Earnings Scheduled For February 22, 2023
Companies Reporting Before The Bell
• Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022.
Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment
The FDA granted accelerated approval to Travere Therapeutics Inc’s (NASDAQ:TVTX) Filspari (sparsentan) to reduce proteinuria in adults with primary IgAN at risk…
Sermonix Pharmaceuticals’ Lasofoxifene, Will Be Evaluated In A New Study Arm Of The Ongoing I-SPY Endocrine Program Sponsored By Quantum Leap Healthcare Collaborative, In Newly Diagnosed ER+ Invasive Cancer, Lasofoxifene Was In-Licensed From Ligand Pha…
The arm is part of the I-SPY 2 Endocrine Optimization Platform (EOP), which is focused on patients with clinically high-risk (stage 2/3) estrogen receptor-positive (ER+)/HER2- breast cancer, but the molecularly